Sle disease management
AssigneesImmunarray Ltd., Yeda Research and Development Co. Ltd.
InventorsRachel SOREK, Keren JAKOBI-BROOK, Pennina SAFER, Irun R. COHEN
Life of this patent
Estimating the term…
Abstract
Assays, kits and methods useful in the field of systemic lupus erythematosus (SLE) diagnosis and management for determining and providing SLE treatment adjustment include methods for detecting SLE resolution and for adjusting treatment in a subject hitherto diagnosed as having SLE.
Claims21
1-28. (canceled)
A method for adjusting treatment in a subject having been diagnosed as having systemic lupus erythematosus (SLE) at least three years earlier, the method comprising the steps of:
- (i) providing a first sample obtained from the subject at a first time point and a second sample obtained from the same subject at a second, subsequent time point;
- (ii) exposing antibodies in each of the two samples to at least four antigens selected from the group consisting of:
- ssDNA, Sm, DNAse I, Histone III-S, Ro52, U1 snRNP, Collagen III, Apo-SAA, H2a, and Oligo21 to detect the respective reactivity patterns of the two samples to the at least four antigens;
- (iii) calculating scores based on the reactivity patterns of the two samples by a supervised classification algorithm, wherein the lower the score the greater is the probability that the subject is not afflicted with SLE;
- (iv) comparing the scores obtained for the two samples;
- and
- (v) determining that the subject is amenable for treatment adjustment if there is a significant reduction of the score obtained for the second sample compared to the score obtained for the first sample.
A method for detecting resolution of systemic lupus erythematosus (SLE) in a subject having been diagnosed as having SLE, the method comprising the steps of:
- (i) providing a first sample obtained from the subject at a first time point and a second sample obtained from the same subject at a second, subsequent time point, wherein the subject has been diagnosed as having SLE at least three years earlier of the second time point and is asymptomatic at the second time point;
- (ii) exposing antibodies in each of the two samples to at least four antigens selected from the group consisting of:
- ssDNA, Sm, DNAse I, Histone III-S, Ro52, U1 snRNP, Collagen III, Apo-SAA, H2a, and Oligo21 to detect the respective reactivity patterns of the two samples to the at least four antigens;
- (iii) calculating scores based on the reactivity patterns of the two samples by a supervised classification algorithm, in which the lower the score the greater is the probability that the subject is not afflicted with SLE;
- (iv) comparing the scores obtained for the two samples;
- and
- (v) determining that the subject has SLE resolution if there is a significant reduction of the score obtained for the second sample compared to the score obtained for the first sample.
Dependencies are inferred from the claim text.